Enveric Biosciences (NASDAQ:ENVB – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($6.00) per share for the quarter.
Enveric Biosciences Stock Up 5.5 %
Shares of ENVB opened at $1.73 on Monday. The stock’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $5.23. The firm has a market capitalization of $1.17 million, a PE ratio of -0.05 and a beta of 0.47. Enveric Biosciences has a 12-month low of $1.13 and a 12-month high of $28.05.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Enveric Biosciences in a report on Thursday, March 6th.
Enveric Biosciences Company Profile
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Featured Stories
- Five stocks we like better than Enveric Biosciences
- Are Penny Stocks a Good Fit for Your Portfolio?
- How to Build the Ultimate Everything ETF Portfolio
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
